Fortress Biotech (FBIO) Net Equity Issued and Repurchased (2010 - 2025)

Fortress Biotech's Net Equity Issued and Repurchased history runs 15 years deep, the most recent figure standing at -$1000.0 for Q2 2025.

• In Q2 2025, Net Equity Issued and Repurchased fell 100.05% year-over-year to -$1000.0; the TTM figure through Dec 2025 stood at $1.0 million (down 73.0% YoY), while the FY2025 annual figure was $1.0 million, down 73.0% from the prior year.
• Net Equity Issued and Repurchased for Q2 2025 stood at -$1000.0, down from $1.0 million in the prior quarter.
• The five-year high for Net Equity Issued and Repurchased was $6.3 million in Q4 2021, with the low at -$15000.0 in Q4 2023.
• The 5-year median for Net Equity Issued and Repurchased is $644500.0 (2023), against an average of $1.3 million.
• The sharpest annual moves came in 2023 and 2024: Net Equity Issued and Repurchased tumbled 104.95% in 2023, then surged 2366.67% in 2024.
• Fortress Biotech's Net Equity Issued and Repurchased stood at $6.3 million in 2021, then sank by 95.22% to $303000.0 in 2022, then sank by 104.95% to -$15000.0 in 2023, then soared by 2366.67% to $340000.0 in 2024, then tumbled by 100.29% to -$1000.0 in 2025.
• Business Quant data shows FBIO's Net Equity Issued and Repurchased at -$1000.0 in Q2 2025, $1.0 million in Q1 2025, and $340000.0 in Q4 2024.